Morgan Stanley Calls Seagen (SGEN) A Catalyst Driven Idea for 'Pivotal Padcev Data in 1L Bladder Cancer'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seagen (SGEN) Seen Worth $200+ in a Takeover
June 21, 2022 12:53 PM EDTSeagen (NASDAQ: SGEN) is adding to Friday's gains as traders handicap the sale of the company following reports on Friday from the WSJ that Merck (NYSE: MRK) and others are eyeing a takeover of the biotech company.
Several analysts have weighed in on the potential deal and many view $200+ as the benchmark needed to get the deal done.
Oppenheimer analyst Jay Olson raised his price target on Seagen to $208 per share following the Merck speculation, which he thinks makes sense given recent dynamics, including:
1) SGEN and MRK... More
Seagen (SGEN) PT Raised to $208 at Oppenheimer Amid Merck Takeover Rumors
June 21, 2022 8:10 AM EDTOppenheimer analyst Jay Olson raised the price target on Seagen (NASDAQ: SGEN) to $208.00 (from $160.00) while maintaining a Outperform rating following Merck (NYSE: MRK) takeover rumors.
The analyst commented, "According to the Wall Street Journal (6/17), SGEN has become a... More
Increasing unusual option volume: FSK AND PACB SGEN
June 21, 2022 4:37 AM EDTIncreasing unusual option volume: FSK AND PACB SGEN
... MoreMerck considering purchase of cancer drug maker Seagen - WSJ
June 17, 2022 11:16 AM EDT(Reuters) - Drugmaker Merck & Co is considering buying cancer-focused biotech company Seagen Inc, the Wall Street Journal reported on Friday, citing people familiar with the matter.
Talks have been underway for a while and a deal is not imminent because of heightened risk of a regulatory challenge, the Journal... More
Merck (MRK) Looks to Acquire Seagen (SGEN) - WSJ
June 17, 2022 10:49 AM EDTAccording to a report by The Wall Street Journal on Friday, Merck (NYSE: MRK), the pharmaceutical colossus, is looking into the acquisition of Seagen Inc. (NASDAQ: SGEN).
Seagen is an American biotechnology company based in... More
Seagen (SGEN) Halted on Volatility
June 17, 2022 10:31 AM EDTSeagen (NASDAQ: SGEN) Halted on Volatility
... MoreMerck (MRK) Eyes Purchase of Seagen (SGEN) - WSJ
June 17, 2022 10:31 AM EDT(Updated - June 17, 2022 10:34 AM EDT)
Merck (NYSE: MRK) is examining a purchase of Seagen (NASDAQ: SGEN), according to the Wall Street Journal, citing people familiar with the matter.
The report said... More
